Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Andrew Johnson

Dermatology Naperville, IL Medical Doctor

NPI 1619310232 CMS profile 4216567

263 Shuman Blvd Ste 125, Naperville, IL 60563

Open in the dashboard

General payments

$1,096

40 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Andrew Johnson of Naperville, IL is reported in the CMS Open Payments database as having received $1,096 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $139 1
2023 General $60 1
2020 General $83 4
2019 General $814 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Johnson
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Andrew Johnson were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Andrew Johnson Dermatology median Middle half National median
2019 $814 $454 $129–$1,240 $163
2020 $83 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $60 $607 $159–$1,674 $160
2024 $139 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $192 10 payments
  2. Amgen Inc. $148 3 payments
  3. Davol Inc. $139 1 payment
  4. Regeneron Healthcare Solutions, Inc. $111 2 payments
  5. Sun Pharmaceutical Industries Inc. $91 4 payments
  6. Sanofi-Aventis U.S. LLC $60 1 payment
  7. Genzyme Corporation $55 3 payments
  8. Novartis Pharmaceuticals Corporation $54 3 payments
  9. Galderma Laboratories, L.P. $40 2 payments
  10. Lilly USA, LLC $38 2 payments
  11. Other $168 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,036 39 payments
  2. Education $60 1 payment
Products named General payments · program years 2019–2024
  1. SKYRIZI $170 9 payments
  2. Enbrel $148 3 payments
  3. Phasix Mesh $139 1 payment
  4. HUMIRA $116 6 payments
  5. LIBTAYO $91 1 payment
  6. DUPIXENT $83 2 payments
  7. COSENTYX $54 3 payments
  8. ABSORICA $44 2 payments
  9. TALTZ $38 2 payments
  10. LEVULAN KERASTICK $37 2 payments
  11. Other $285 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

553

Median for Dermatology: 534

Drug cost

$222,514

Median for Dermatology: $67,151

Branded share of claims

9.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 19 $160,345
Dupixent Pen Dupilumab Brand 11 $41,031
Clobetasol Propionate Generic 72 $3,827
Tacrolimus Generic 24 $3,809
Calcipotriene Generic 20 $3,235
Ketoconazole Generic 137 $2,050
Doxycycline Hyclate Generic 25 $1,654
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 12 $1,407
Fluorouracil Generic 20 $1,262
Triamcinolone Acetonide Generic 108 $1,200

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$83,895

Medicare's payments for the services billed

Medicare patients

398

Average age 73

Services billed

1,717

177 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 47%
Ischemic heart disease 28%
Diabetes 22%
Chronic kidney disease 16%
Atrial fibrillation 15%
Heart failure 14%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record